JP2019512262A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019512262A5 JP2019512262A5 JP2018560245A JP2018560245A JP2019512262A5 JP 2019512262 A5 JP2019512262 A5 JP 2019512262A5 JP 2018560245 A JP2018560245 A JP 2018560245A JP 2018560245 A JP2018560245 A JP 2018560245A JP 2019512262 A5 JP2019512262 A5 JP 2019512262A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- antibody
- acid sequence
- amino acid
- nucleic acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP16154507.4A EP3202788A1 (en) | 2016-02-05 | 2016-02-05 | Endosialin-binding antibody |
| EP16154507.4 | 2016-02-05 | ||
| PCT/EP2017/052399 WO2017134234A1 (en) | 2016-02-05 | 2017-02-03 | Endosialin-binding antibody |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019512262A JP2019512262A (ja) | 2019-05-16 |
| JP2019512262A5 true JP2019512262A5 (https=) | 2020-03-12 |
| JP7094893B2 JP7094893B2 (ja) | 2022-07-04 |
Family
ID=55310735
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018560245A Expired - Fee Related JP7094893B2 (ja) | 2016-02-05 | 2017-02-03 | エンドシアリン結合抗体 |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US11318210B2 (https=) |
| EP (2) | EP3202788A1 (https=) |
| JP (1) | JP7094893B2 (https=) |
| AU (1) | AU2017216284A1 (https=) |
| CA (1) | CA3012270A1 (https=) |
| WO (1) | WO2017134234A1 (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3773739A1 (en) * | 2018-04-12 | 2021-02-17 | MediaPharma S.r.l. | Lgals3bp antibody-drug-conjugate and its use for the treatment of cancer |
| EP3880706A1 (en) * | 2018-11-12 | 2021-09-22 | MediaPharma S.r.l. | Bispecific antibodies directed against human 90k and either endosialin or her3 |
| US20220088231A1 (en) | 2018-12-03 | 2022-03-24 | Fusion Pharmaceuticals Inc. | Radioimmunoconjugates and dna damage and repair inhibitor combination therapy |
| EP3976091A4 (en) * | 2019-05-31 | 2023-07-26 | Ludwig Institute for Cancer Research Ltd | ANTI-TEM1 ANTIBODIES AND THEIR ANTIGEN-BINDING PARTS |
| KR20220111313A (ko) | 2019-12-06 | 2022-08-09 | 아블린쓰 엔.브이. | TNFα 및 OX40L을 표적으로 하는 면역글로불린 단일 가변 도메인을 포함하는 폴리펩티드 |
| WO2021207086A1 (en) * | 2020-04-06 | 2021-10-14 | Fusion Pharmaceuticals Inc. | Tem-1-targeted radioimmunoconjugates and uses thereof |
| EP4263602A1 (en) | 2020-12-18 | 2023-10-25 | Ablynx N.V. | Polypeptides comprising immunoglobulin single variable domains targeting il-6 and tnf-alpha |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| WO1989009622A1 (en) | 1988-04-15 | 1989-10-19 | Protein Design Labs, Inc. | Il-2 receptor-specific chimeric antibodies |
| IL162181A (en) | 1988-12-28 | 2006-04-10 | Pdl Biopharma Inc | A method of producing humanized immunoglubulin, and polynucleotides encoding the same |
| WO2006017759A2 (en) * | 2004-08-05 | 2006-02-16 | Kirin Brewery Co., Ltd. | Tumor endothelial marker-1 (tem1) binding antibodies and uses thereof |
| ITRM20090081A1 (it) | 2009-02-25 | 2010-08-26 | Stefano Iacobelli | Uso di inibitori della proteina 90k per la preparazione di un medicamento per la cura o prevenzione dei tumori. |
| WO2010118203A2 (en) * | 2009-04-09 | 2010-10-14 | Morphotek, Inc. | Endosialin binding molecules |
| JPWO2012176779A1 (ja) * | 2011-06-20 | 2015-02-23 | 協和発酵キリン株式会社 | 抗ｅｒｂＢ３抗体 |
| WO2013148250A1 (en) * | 2012-03-30 | 2013-10-03 | Morphotek, Inc. | Tem-1 diagnostic antibodies |
-
2016
- 2016-02-05 EP EP16154507.4A patent/EP3202788A1/en not_active Ceased
-
2017
- 2017-02-03 EP EP17703724.9A patent/EP3411405A1/en not_active Withdrawn
- 2017-02-03 WO PCT/EP2017/052399 patent/WO2017134234A1/en not_active Ceased
- 2017-02-03 JP JP2018560245A patent/JP7094893B2/ja not_active Expired - Fee Related
- 2017-02-03 CA CA3012270A patent/CA3012270A1/en active Pending
- 2017-02-03 AU AU2017216284A patent/AU2017216284A1/en not_active Abandoned
- 2017-02-03 US US16/075,849 patent/US11318210B2/en active Active
-
2022
- 2022-03-29 US US17/707,838 patent/US20220218836A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019512262A5 (https=) | ||
| US11718681B2 (en) | Anti-SIRP α antibodies | |
| JP7401126B2 (ja) | 抗ｃｕｂドメイン含有タンパク質１（ｃｄｃｐ１）抗体、抗体薬物コンジュゲート、およびその使用方法 | |
| JP2017510559A5 (https=) | ||
| JP7785284B2 (ja) | Ｃｄ３８抗体とｉｃａｍ１抗体およびそれらの使用 | |
| JP2016523810A5 (https=) | ||
| JP2021531764A5 (https=) | ||
| FI3218005T3 (fi) | Glykaanin kanssa vuorovaikutteisia yhdisteitä ja käyttömenetelmiä | |
| RU2020124944A (ru) | Антитела против egfr и конъюгаты антитело-лекарственное средство | |
| JP2018506961A5 (https=) | ||
| JP2015509947A5 (https=) | ||
| JP2010536378A5 (https=) | ||
| JP2023022328A5 (https=) | ||
| JP2017522861A5 (https=) | ||
| JP2015523961A5 (https=) | ||
| JP2014531201A5 (https=) | ||
| JP2016538318A5 (https=) | ||
| US20250034273A1 (en) | Composition of multispecific antibodies targeting cadherin-17-expressing tumors and method of making and using thereof | |
| JP2022533538A5 (https=) | ||
| JP2020522280A5 (https=) | ||
| JP7094893B2 (ja) | エンドシアリン結合抗体 | |
| JP2020522281A5 (https=) | ||
| JP2017521054A5 (https=) | ||
| JP2024509018A5 (https=) | ||
| WO2025061181A1 (en) | Anti-cdh17 antibodies and uses thereof |